Company intelligence / Profile preview

JiKang Therapeutics

Shanghai Shi, China

Ownership: Private
Development stage: Other

Overview

JiKang Therapeutics has developed a preclinical nanobody (single-domain antibody) APJ agonist that demonstrates at least 10-fold greater potency than natural apelin and is being advanced toward IND-enabling studies. Preclinical results show enhanced weight-loss efficacy in combination with GLP-1 receptor agonists, improved body composition, and muscle function.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Nanobody therapyAntibodyBiologic
Industry: Biotech

Partnerships

BioAge LabsXtalPi

Beyond the preview

Go deeper on JiKang Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JiKang Therapeutics.

Explore the full profile